Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)

Cell-free DNA (cfDNA) is an attractive cancer biomarker, as it is thought to reflect a component of the underlying genetic makeup of the tumor and is readily accessible in serial fashion. Because chemotherapy ...
Source: BMC Research Notes - Category: Research Authors: Tags: Research note Source Type: research

Related Links:

We reviewed the literature for the biologic, prognostic, and predictive significance of circulating prostate cancer tumor cells (CTCs), and circulating tumor DNA (ctDNA) in the blood of metastatic castration resistant prostate cancer patients (mCRPC). CTCs demonstrate robust prognostic value independent of PSA in predicting overall survival. The CTC androgen receptor variant receptor 7 (AR-V7) phenotype predicts resistance to androgen receptor synthesis inhibitors and sensitivity to taxane based chemotherapy in mCRPC patients who are candidates for second line therapy.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionsHigh expression of GHET1 was related with the low sensitivity to Gemcitabine of BC; GHET1 contributed to chemotherapeutic resistance to Gemcitabine in BC through up-regulating ABCC1 expression. Our findings are helpful to expound the molecular mechanism of chemotherapeutic resistance in BC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Publication date: September 2019Source: Biomedicine &Pharmacotherapy, Volume 117Author(s): Xueni Wang, Yuting Yang, Yating An, Gang FangAbstractIn the last century, natural compounds have achieved remarkable achievements in the treatment of tumors through chemotherapy. This inspired scientists to continuously explore anticancer agents from natural compounds. Kaempferol is an ordinary natural compound, the most common flavonoid, which is widely existed in vegetables and fruits. It has been reported to have various anticancer activities, including breast cancer, prostate cancer, bladder cancer, cervical cancer, colon can...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Cabazitaxel (CBZ) chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) is believed to be palliative because the radiological response rate is low and a durable response is rare. Here, we de...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Case report Source Type: research
ConclusionsPatients with somatic Wnt-pathway activating mutations have worse outcomes to first-line abiraterone/enzalutamide than Wnt wild-type patients. Our data suggest that additional genomically informed therapies are needed for this relevant subset of mCRPC patients.Patient summaryIn this report, we retrospectively examined outcomes of metastatic prostate cancer patients with or without Wnt-pathway mutations who received abiraterone or enzalutamide for the first time, in order to examine whether these mutations affect the prognosis. Our study suggested that patients who have Wnt-pathway activating mutations derived le...
Source: European Urology - Category: Urology & Nephrology Source Type: research
We report a case of 75-year-old man with metastatic cholangiocarcinoma to liver and lymph nodes progressing on chemotherapy. 68Ga-PSMA PET/CT was performed to assess PSMA expression and showed additional bone and hepatic lesions compared with 18F-FDG PET/CT. 68Ga-PSMA expression in the metastatic cholangiocarcinoma potentially guides radionuclide legend therapy with α/β-emitters especially after enervation of all approved therapeutic options.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
We present the case of a 56 year old male who presented with diffusely worsening back pain along with scrotal swelling who was ultimately diagnosed with metastatic prostate cancer to the bilateral testicles.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Purpose of review An overview of urologic malignancies in Lynch syndrome and the current state of research. Recent findings Upper tract urothelial carcinoma (UTUC) is the third most common malignancy in Lynch syndrome. Establishment and utilization of a sensitive and practical screening method for Lynch syndrome in patients presenting with UTUC is overdue. Next-generation sequencing to evaluate for microsatellite instability (MSI) and detect mutations of mismatch repair (MMR) genes may be the future of Lynch syndrome screening. Epidemiologic data and molecular characterization suggest bladder urothelial carcinoma (BUC...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: CANCER GENETICS IN UROLOGIC PRACTICE: Edited by Todd M. Morgan and Brian Chapin Source Type: research
Purpose of review The utility of tumor genetic testing in metastatic prostate cancer is rapidly evolving – especially in respect to finding prognostic and predictive biomarkers. In this review, we describe genomic aberrations in clinically relevant pathways in metastatic castration-resistant prostate cancer (mCRPC) for which therapeutic targeting is possible. Recent findings Recognizing the diverse array of genetic features within prostate cancer, the goal of testing in mCRPC is to match an individual patients’ tumor with the best therapy. Approximately 20–25% of mCRPC patients have defects in DNA re...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: CANCER GENETICS IN UROLOGIC PRACTICE: Edited by Todd M. Morgan and Brian Chapin Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Genetics | Prostate Cancer | Research